SpringWorks Therapeutics (NASDAQ:SWTX), which is reportedly in takeover talks with Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY), has received FDA approval for the drug mirdametinib for the treatment of ...
P-gp and BCRP Substrates: Avoid concomitant use of sensitive substrates of P-gp and BCRP with FILSPARI. Sparsentan may increase exposure of these transporter substrates, which may increase the risk of ...